INS and type 2 diabetes mellitus: Clinical studies have shown that mealtime subcutaneous pramlintide along with insulin, could regulate postprandial glucose appearance [10, 11], slow gastric emptying [12], suppress postprandial glucagon secretion [13], spare mealtime insulin use with benefit of overall weight loss [3, 14], reduce frequency of hemoglobin A1c (HbA1c) and food intake [15, 16] in both type 1 and type 2 diabetes [17-20].